- Conditions
- Sarcoma, Giant Cell Tumor of Bone
- Interventions
- Surgery
- Procedure
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 158
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease
- Interventions
- CPC-201
- Drug
- Lead sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Industry
- Eligibility
- 50 Years to 79 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Dementia Alzheimer's Type
- Interventions
- Sargramostim GZ402664, Placebo, Florbetapir F18
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
- Interventions
- No Intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
- Interventions
- PACE Program
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Chapel Hill, North Carolina
- Conditions
- Alzheimer Disease
- Interventions
- xaliproden (SR57746A)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, 11C-PIB
- Drug
- Lead sponsor
- José A. Luchsinger
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Aerobic Exercise
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer's Disease, Obesity, Diabetes Mellitus
- Interventions
- Boost (R) 5-2 diet, Healthy Living Diet
- Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
- Conditions
- Dementia, Alzheimer Type
- Interventions
- ABC Clinical Program, BCN
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Alzheimer's Disease
- Interventions
- CPC-201, Positron emission tomography (PET)
- Drug · Other
- Lead sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Industry
- Eligibility
- 50 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- West Bloomfield, Michigan
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- Remternetug (SC), Matching Placebo (Remternetug)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2034
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- MPC-7869
- Drug
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 20 more
- Conditions
- Dementia of the Alzheimer's Type
- Interventions
- CPC-201
- Drug
- Lead sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Miami, Florida • Pompano Beach, Florida • West Palm Beach, Florida + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- HiDO-ALZ
- Device
- Lead sponsor
- HiDO Technologies
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease, Parkinson, Tremor Essential, Dementia, Alzheimer Type, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia With Lewy Bodies, Dementia Frontal
- Interventions
- Not listed
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- grape seed polyphenolic extract, resveratrol
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- AL Amyloidosis
- Interventions
- Ixazomib, Cyclophosphamide, Dexamethasone
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712, Placebo Oral Tablet
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 37
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Interventions
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Device · Behavioral
- Lead sponsor
- Boston University
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 111
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Agitation in Participants With Dementia of the Alzheimer's Type
- Interventions
- AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more